ii. capturing the Reactant* in the DZ in an amount related to the amount of analyte in the sample,

wherein

A) the Reactant* has labeled particles as an analytically detectable group, and

B) the Capturer is anchored to the matrix via immobilized particles which exhibit hydrophilic groups on their surface.--

--43. (NEW) The method according to claim 42, wherein immobilization of a biospecific affinity reactant by covalent binding is to the hydrophilic groups on the Capturer particles.--

Sub C1

--44. (NEW) The method according to claim 42, wherein immobilization of a complex mixture of biospecific affinity reactants is to the hydrophilic groups on the Capturer particles.--

--45. (NEW) The method according to claim 42, wherein immobilization of a complex mixture of biospecific affinity reactants found in allergen extracts is to the hydrophilic groups on the Capturer particles.--

B1

--46. (NEW) The method according to claim 42, wherein immobilization of a complex mixture of biospecific affinity reactants found in biological material used to detect autoantibodies is to the hydrophilic groups on the Capturer particles.--

--47. (NEW) The method according to claim 42, wherein the hydrophilic grops are hydroxy, carboxy, amino or sulphonate groups.--

--48. (NEW) The method according to claim 42, wherein the analyte is an antibody of IgE or IgG type with specificity to allergens.--

--49. (NEW) The method according to claim 42, wherein the analyte is an antibody of IgG, IgM or IgA type with specificity to autoantigens.--

Sub. C1

--50. (NEW) The method according to claim 42, wherein the particles anchoring the Capturer have a size which is smaller than a smallest inner dimension of the flow channels of the matrix.--

--51. (NEW) The method according to claim 42, wherein the particles which anchor the Capturer have a size in the range of 0.1-1000 μm.--

--52. (NEW) The method according to claim 42, wherein the particles which anchor the Capturer have a size in the range of 0.1-100 μm.--

--53. (NEW) The method according to claim 42, wherein the labeled particles in the Reactant* have a diameter in the range of 0.01-5 μm.--

B1

--54. (NEW) The method according to claim 42, wherein the flow channels have a smallest inner diameter in the range of 0.4-1000 μm.--

--55. (NEW) The method according to claim 42, wherein the flow channels have a smallest inner dimension in the range of 0.4-100 μm.--

--56. (NEW) The method according to claim 42, wherein the labeled particles are fluorescent or coloured.--

--57. (NEW) The method according to claim 42, wherein the Reactant* is predeposited in the matrix upstream of the DZ.--

--58. (NEW) The method according to claim 57, wherein the Reactant* is predeposited in the matrix upstream of a sample application site.--

Sub. C1

--59. (NEW) The method according to claim 42, wherein the particles which anchor the Capturer to the matrix are a synthetic polymer, a semisynthetic polymer or a biopolymer, which on its surface exhibits hydrophilic groups.--

--60. (NEW) The method according to claim 42, wherein the Reactant* is captured in the DZ by formation of a ternary complex of Reactant'---analyte---Reactant*, wherein the Reactant* binds to the analyte simultaneously or in sequence and Reactant' is the firmly anchored Capturer or a reactant to which the Capturer may bind by biospecific affinity.--

B1

--61. (NEW) The method according to claim 60, wherein the analyte is an antigen and the Reactant' and Reactant* are antibodies with specificity for epitopes on the analyte.--

--62. (NEW) The method according to claim 42, wherein the method is performed in connection with diagnosing allergy or autoimmune disease.--

--63. (NEW) A test kit when used for performing analytical methods in a flow matrix, which methods utilize biospecific affinity reactions to detect an analyte in a sample, which kit comprises (i) a flow matrix having a detection zone (DZ), in which there is a firmly anchored biospecific affinity reactant (Capturer), and (ii) and analytically detectable reactant (Reactant*),

wherein

A) the Reactant* has labeled particles as an analytically detectable group, and

B) the Capturer is anchored to the matrix via immobilized particles which exhibit hydrophilic groups on their surface.--

Subc1

--64. (NEW) The kit according to claim 63, wherein immobilization of a biospecific affinity reactant by covalent binding is to the hydrophilic groups on the Capturer particles.--

--65. (NEW) The kit according to claim 63, wherein immobilization of a complex mixture of biospecific affinity reactants is to the hydrophilic groups on the Capturer particles.--

b1

--66. (NEW) The kit according to claim 63, wherein immobilization of a complex mixture of biospecific affinity reactants found in allergen extracts is to the hydrophilic groups on the Capturer particles.--

--67. (NEW) The kit according to claim 63, wherein immobilization of a complex mixture of biospecific affinity reactants found in biological material used to detect autoantibodies is to the hydrophilic groups on the Capturer particles.--

--68. (NEW) The kit according to claim 63, wherein the hydrophilic groups are hydroxy, carboxy, amino or sulphonate groups.--

--69. (NEW) The kit according to claim 63, wherein the analyte is an antibody of IgE or IgG type with specificity to allergens.--

Subc1

--70. (NEW) The kit according to claim 63, wherein the analyte is an antibody of IgG, IgM or IgA type with specificity to autoantigens.--

--71. (NEW) The kit according to claim 63, wherein the particles anchoring the Capturer have a size which is smaller than a smallest inner dimension of the flow channels of the matrix.--

--72. (NEW) The kit according to claim 63, wherein the particles which anchor the Capturer have a size in the range of 0.1-1000 μm.--

--73. (NEW) The kit according to claim 63, wherein the particles which anchor the Capturer have a size in the range of 0.1-100 μm.--

b1

--74. (NEW) The kit according to claim 63, wherein the labeled particles in the Reactant* have a diameter in the range of 0.01-5 μm.--

--75. (NEW) The kit according to claim 63, wherein the flow channels have a smallest inner dimension in the range of 0.4-1000 μm.--

--76. (NEW) The kit according to claim 63, wherein the flow channels have a smallest inner dimension in the range of 0.4-100 μm.--

--77. (NEW) The kit according to claim 63, wherein the labeled particles are fluorescent or coloured.--

Subc1

--78. (NEW) The kit according to claim 63, wherein the Reactant* is predeposited in the matrix upstream of the DZ.--

--79. (NEW) The kit according to claim 78, wherein the Reactant* is predeposited in the matrix upstream of a sample application site.--

--80. (NEW) The kit according to claim 63, wherein the particles which anchor the Capturer to the matrix are a synthetic polymer, a semisynthetic polymer or a biopolymer, which on its surface exhibits hydrophilic groups.--

--81. (NEW) The kit according to claim 63, wherein the Reactant* is captured in the DZ by formation of a ternary complex of Reactant'---analyte---Reactant*, wherein the Reactant* binds to the analyte simultaneously or in sequence and Reactant' is the firmly anchored Capturer or a reactant to which the Capturer may bind by biospecific affinity.--

D1

--82. (NEW) The kit according to claim 81, wherein the analyte is an antigen and the Reactant' and Reactant* are antibodies with a specificity for epitopes on the analyte.--

Bl Cancel Sub.C1

--83. (NEW) The kit according to claim 63, wherein the method is performed in connection with diagnosing allergy or autoimmune disease.--

In the Abstract:

Please add the following abstract to follow the claims of the application: